Portal de investigación
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Monreal E
- Fernández-Velasco JI
- Álvarez-Lafuente R
- Sainz de la Maza S
- García-Sánchez MI
- Llufriu S
- Comabella M
- Martínez-Yélamos S
- Galimberti D
- Ramió-Torrentà L
- Martínez-Ginés ML
- Aladro Y
- Ayuso L
- Martínez-Rodríguez JE
- Brieva L
- Villarrubia N
- Eichau S
- Zamora J
- Rodero-Romero A
- Espiño M
- Blanco Y
- Saiz A
- Montalbán X
- Tintoré M
- Domínguez-Mozo MI
- Cuello JP
- Romero-Pinel L
- Ghezzi L
- Pilo de la Fuente B
- Quiroga-Varela A
- Rubio L
- Rodríguez-Jorge F
- Chico-García JL
- Sainz-Amo R
- Masjuan J
- Costa-Frossard L
- Villar LM
Grupos
Abstract
The potential of combining serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels to predict disability worsening in multiple sclerosis (MS) remains underexplored. We aimed to investigate whether sNfL and sGFAP values identify distinct subgroups of patients according to the risk of disability worsening and their response to disease-modifying treatments (DMTs). This multicentre study, conducted across thirteen European hospitals, spanned from July 15, 1994, to August 18, 2022, with follow-up until September 26, 2023. We enrolled MS patients who had serum samples collected within 12 months from disease onset and before initiating DMTs. Multivariable regression models were used to estimate the risk of relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and Expanded Disability Status Scale (EDSS) score of 3. Of the 725 patients included, median age was 34.2 years (IQR, 27.6-42.4), and 509 patients (70.2%) were female. Median follow-up duration was 6.43 years (IQR, 4.65-9.81). Higher sNfL values associated with an elevated risk of RAW (HR of 1.45; 95% CI 1.19-1.76; P < 0.001), PIRA (HR of 1.43; 95% CI 1.13-1.81; P = 0.003), and reaching an EDSS of 3 (HR of 1.55; 95% CI 1.29-1.85; P < 0.001). Moreover, higher sGFAP levels were linked to a higher risk of achieving an EDSS score of 3 (HR of 1.36; 95% CI 1.06-1.74; P = 0.02) and, in patients with low sNfL values, to PIRA (HR of 1.86; 95% CI 1.01-3.45; P = 0.04). We further examined the combined effect of sNfL and sGFAP levels. Patients with low sNfL and sGFAP values (NLGL) exhibited a low risk of all outcomes and served as reference. Untreated patients with high sNfL levels showed a higher risk of RAW, PIRA, and reaching an EDSS of 3. Injectable or oral DMTs reduced the risk of RAW in these patients but failed to mitigate the risk of PIRA and reaching an EDSS of 3. Conversely, high-efficacy DMTs counteracted the heightened risk of these outcomes, except for the risk of PIRA in patients with high sNfL and sGFAP levels. Patients with low sNfL and high sGFAP values (NLGH) showed an increased risk of PIRA and achieving an EDSS of 3, which remained unchanged with either high-efficacy or other DMTs. In conclusion, evaluating sNfL and sGFAP levels at disease onset in MS may identify distinct phenotypes associated with diverse immunological pathways of disability acquisition and therapeutic response.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Datos de la publicación
- ISSN/ISSNe:
- 0006-8950, 1460-2156
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 39101570
- Factor de Impacto:
- 4,573 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BRAIN OXFORD UNIV PRESS
Citas Recibidas en Web of Science: 46
Documentos
- No hay documentos
Filiaciones
Keywords
- clinically isolated syndrome; glial fibrillary acidic protein; multiple sclerosis; neurofilament light chain; progression
Campos de Estudio
Cita
Monreal E,Fernández JI,Álvarez R,Sainz de la Maza S,García MI,Llufriu S,CASANOVA B,Comabella M,Martínez S,Galimberti D,Ramió L,Martínez ML,Aladro Y,Ayuso L,Martínez JE,Brieva L,Villarrubia N,Eichau S,Zamora J,Rodero A,Espiño M,Blanco Y,Saiz A,Montalbán X,Tintoré M,Domínguez MI,Cuello JP,Romero L,Ghezzi L,Pilo de la Fuente B,PÉREZ F,Quiroga A,Rubio L,Rodríguez F,Chico JL,Sainz R,Masjuan J,Costa L,Villar LM. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain. 2024. IF:11,700. (1).